| 22.8 -0.4 (-1.72%) | 10-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.28 |
1-year : | 30.58 |
| Resists | First : | 24.21 |
Second : | 26.19 |
| Pivot price | 22.83  |
|||
| Supports | First : | 21.02 | Second : | 17.48 |
| MAs | MA(5) : | 23.65 |
MA(20) : | 22.89 |
| MA(100) : | 29.25 |
MA(250) : | 32.3 |
|
| MACD | MACD : | -0.7 |
Signal : | -1 |
| %K %D | K(14,3) : | 57.7 |
D(3) : | 66.9 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 42.2 | Low : | 21.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAMS ] has closed above bottom band by 49.0%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 23.26 - 23.4 | 23.4 - 23.5 |
| Low: | 21.91 - 22.09 | 22.09 - 22.23 |
| Close: | 22.56 - 22.83 | 22.83 - 23.03 |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Fri, 02 Oct 2026
After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. - Stock Titan
Fri, 02 Oct 2026
Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. - Stock Titan
Fri, 02 Oct 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Tue, 22 Sep 2026
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
Tue, 22 Sep 2026
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 8.29e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 9,180 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.4416e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 752.6 % |
| Return on Equity (ttm) | -20.2 % |
| Qtrly Rev. Growth | 7.12e+006 % |
| Gross Profit (p.s.) | -896.67 |
| Sales Per Share | -409 |
| EBITDA (p.s.) | 7.91111e+007 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0.38 |
| Dividend | 0 |
| Forward Dividend | 1.265e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|